Vimeo
LinkedIn
Instagram
Share |

life science

March 10, 2022

Companies developing robotic assistance for spine surgery, innovative treatment of cataracts, 3D cardiac modelling software, extracorporeal respiratory support systems and therapy for glaucoma surgery scar prophylaxis will exclusively present in-person as Campden Wealth returns to Lausanne, Switzerland, for the 32nd edition of the MedTech Investing Forum on June 6 and 7.

Companies developing robotic assistance for spine surgery, innovative treatment of cataracts, 3D cardiac modelling software, extracorporeal respiratory support systems and therapy for glaucoma surgery scar prophylaxis will exclusively present in-person as Campden Wealth returns to Lausanne, Switzerland, for the 32nd edition of the MedTech Investing Forum on June 6 and 7.

August 13, 2021

Cutting-edge venture stage innovations for chronic diseases with billion-dollar market potential will be presented to private investors at the Campden Wealth 31st MedTech Investing Europe Forum on 21-22 September, 2021.

Cutting-edge venture stage innovations for chronic diseases with billion-dollar market potential will be presented to private investors at the Campden Wealth 31st MedTech Investing Europe Forum on 21-22 September, 2021.

April 28, 2020

The coronavirus pandemic has triggered a race for disruptive innovation in diagnostics, new therapies and novel vaccines, but the global life sciences industry was already expected to reach more than $2 trillion in gross value by 2023, up from $1.6 trillion before the crisis.

The coronavirus pandemic has triggered a race for disruptive innovation in diagnostics, new therapies and novel vaccines, but the global life sciences industry was already expected to reach more than $2 trillion in gross value by 2023, up from $1.6 trillion before the crisis.

Click here >>
Close